Amgen (NASDAQ:AMGN – Get Rating) announced its quarterly earnings data on Thursday. The medical research company reported $4.65 EPS for the quarter, beating the consensus estimate of $4.40 by $0.25, Briefing.com reports. Amgen had a net margin of 24.92% and a return on equity of 188.78%. The company had revenue of $6.59 billion for the quarter, compared to the consensus estimate of $6.53 billion. During the same period in the prior year, the firm posted $4.38 EPS. Amgen’s revenue for the quarter was up 1.0% on a year-over-year basis. Amgen updated its FY22 guidance to $17.00 to $18.00 EPS and its FY 2022 guidance to $17.00-$18.00 EPS.
Amgen Trading Down 0.3 %
Amgen stock opened at $246.25 on Friday. The stock has a market cap of $131.55 billion, a P/E ratio of 20.87, a PEG ratio of 2.04 and a beta of 0.56. The company has a debt-to-equity ratio of 39.31, a current ratio of 1.44 and a quick ratio of 1.09. Amgen has a 1 year low of $198.64 and a 1 year high of $258.45. The firm’s 50 day moving average price is $245.14 and its 200-day moving average price is $239.83.
Amgen Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 8th. Stockholders of record on Thursday, August 18th will be given a dividend of $1.94 per share. This represents a $7.76 annualized dividend and a dividend yield of 3.15%. The ex-dividend date of this dividend is Wednesday, August 17th. Amgen’s payout ratio is currently 65.76%.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently modified their holdings of the business. Lumature Wealth Partners LLC grew its holdings in shares of Amgen by 51.1% in the first quarter. Lumature Wealth Partners LLC now owns 142 shares of the medical research company’s stock valued at $34,000 after purchasing an additional 48 shares in the last quarter. Worth Asset Management LLC purchased a new position in Amgen during the first quarter worth $112,000. Shepherd Financial Partners LLC purchased a new position in Amgen during the first quarter worth $200,000. PFS Investments Inc. purchased a new position in Amgen during the first quarter worth $203,000. Finally, Ergoteles LLC purchased a new position in Amgen during the first quarter worth $219,000. 79.01% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
Several brokerages recently commented on AMGN. Mizuho increased their price objective on shares of Amgen from $202.00 to $208.00 in a research report on Tuesday, May 10th. SVB Leerink began coverage on shares of Amgen in a report on Monday, May 23rd. They set a “market perform” rating and a $256.00 price target on the stock. Royal Bank of Canada raised their price target on shares of Amgen from $224.00 to $236.00 in a report on Friday. StockNews.com raised shares of Amgen from a “buy” rating to a “strong-buy” rating in a report on Monday, May 16th. Finally, BMO Capital Markets dropped their price target on shares of Amgen from $263.00 to $243.00 in a report on Thursday, April 28th. One research analyst has rated the stock with a sell rating, ten have given a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $250.00.
Amgen Company Profile
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization.
- Get a free copy of the StockNews.com research report on Amgen (AMGN)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Why Apple Could Be At All-Time Highs By Year End
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.